STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] MYOMO, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Myomo, Inc. received an amended Schedule 13G reporting that Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively beneficially own 9.9% of Myomo’s common stock. The filing references 38,435,524 shares outstanding as of November 3, 2025.

The reported position reflects 3,790,788 shares of common stock and an additional 3,763,258 pre-funded warrants that are subject to a 9.99% “blocker”, which prevents exercises that would push ownership above that level. As a result, the warrants were not exercisable as of the event date, and the reporting persons indicate passive intent under Schedule 13G certifications.

Positive
  • None.
Negative
  • None.

Insights

Passive 13G/A discloses a capped 9.9% stake with blocker.

Rosalind entities report beneficial ownership of 9.9% in Myomo (MYO), based on 38,435,524 shares outstanding as of November 3, 2025. The stake includes 3,790,788 common shares plus 3,763,258 pre-funded warrants that are contractually restricted.

The warrants carry a 9.99% beneficial ownership limitation, preventing exercises that would push holdings above that threshold. The certification states the securities were acquired and are held in the ordinary course, without intent to influence control.

This is an ownership disclosure rather than a transaction; market impact depends on future holder decisions and any subsequent filings that update share counts or ownership.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 38,435,524 shares of the Issuer's common stock outstanding as of November 3rd, 2025, in accordance with the 10Q filed by the issuer on November 10th. However, as more fully described in Item 4, the securities reported in rows (6), (8), and (9) show the number of shares of Common Stock that would be issuable upon exercise of such reported securities and do not give effect to blocker provisions. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8), and (9). (6) 3,790,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,790,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,790,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,790,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:11/12/2025
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:11/12/2025
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:11/12/2025
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:11/12/2025

FAQ

What stake in MYO does Rosalind report in this Schedule 13G/A?

They report beneficial ownership of 9.9% of Myomo’s common stock.

How many MYO shares and warrants are included in Rosalind’s position?

The filing lists 3,790,788 common shares and 3,763,258 pre-funded warrants subject to a blocker.

What outstanding share count did the filing use for MYO?

It references 38,435,524 shares outstanding as of November 3, 2025.

What is the purpose of the 9.99% blocker on the pre-funded warrants?

It prevents exercising warrants if it would result in beneficial ownership above 9.99% of common stock.

Do the reporting persons indicate a control intent over MYO?

No. The certification states the securities were acquired and are held in the ordinary course, not to change or influence control.

Who are the reporting persons in this MYO 13G/A?

Reported by Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon.
Myomo

NYSE:MYO

MYO Rankings

MYO Latest News

MYO Latest SEC Filings

MYO Stock Data

31.36M
35.63M
6.99%
66.68%
3.84%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
BOSTON